Single | Multiple | ||
---|---|---|---|
(n=35) | (n=20) | ||
Median age (range) | 77 (44–91) | 74 (49–92) | p=0.497 (independent samples t test) |
Sex | |||
Female | 8 | 7 | p=0.331 (χ2 test) |
Male | 27 | 13 | |
Cancer | |||
Oesophageal | 23 | 9 | p=0.134 (χ2 test) |
Gastric | 12 | 11 | |
ASM use | |||
Yes | 8 | 14 | p<0.001 (χ2 test) |
No | 25 | 4 | |
Mean delay to referral, days (SD) | 5 (12.7) | 35 (30.0) | p<0.001 (Mann–Whitney test) |
Tumour stage | |||
≤T3NxM0 | 21 | 12 | p=0.740 (χ2 test) |
>T3NxM0 | 10 | 7 | |
Median length of survival, days (range) | 198 (8–2022) | 639 (51–1834) | p=0.133 (Mann–Whitney test) |
ASM, acid suppression medication (proton pump inhibitors or H2 receptor antagonists).